EQUITY SECURITIES PORTFOLIO INVESTMENT (Tables)

9 Months Ended

Sep. 30, 2022

Investments, Debt and Equity Securities [Abstract]

Unrealized Gain (Loss) on Investments

Equity securities at fair value for the periods presented were comprised of the following:

Security Type	Cost		Gross Unrealized Gain		Gross Unrealized Loss		Fair Value
	(In thousands)
September 30, 2022:
Equity securities - Life Sciences Portfolio (Note 3)	$	38,066	$	19,232	$	(1,014)	$	56,284
Equity securities - other common stock	47,600		8		(22,508)		25,100
Total	$	85,666	$	19,240	$	(23,522)	$	81,384
December 31, 2021:
Equity securities - Life Sciences Portfolio (Note 3)	$	56,037	$	262,811	$	(1,488)	$	317,360
Equity securities - other common stock	43,822		2,068		(1,472)		44,418
Total	$	99,859	$	264,879	$	(2,960)	$	361,778

The following unrealized and realized gains or losses from our investment in the Life Sciences Portfolio are recorded in the change in fair value of equity securities and gain or loss on sale of equity securities, respectively, in the consolidated statements of operations:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
	(In thousands)
Change in fair value of equity securities of public    companies	$	(39,008)	$	243,930	$	(243,106)	$	214,247
Change in fair value of equity securities without readily    determinable fair value	—		(180,023)		—		(102,067)
Gain on sale of equity securities of public    companies	36,397		37,112		101,102		52,167
Net realized and unrealized (loss) gain	$	(2,611)	$	101,019	$	(142,004)	$	164,347